COVID-19 Update: Information and resources can be found here.

News

JoLT-Ca Trial Newsletters

2020

2019

2018

2017

2016 

2015

Milestones

  • January 4, 2016At the start of the new year there are six partner institutions with signed contracts and another six with IRB approval. The six with completed contracts include Anne Arundel Medical Center, Henry Ford Health System, Lifespan Oncology Clinical Research, Ochsner Medical Center, Swedish Cancer Institute, and University of Louisville Physicians. Institutions with IRB approval include CHUM-Notre Dame Hospital, Henry Ford Health System, Lifespan, Swedish Cancer Institute, Ohio State University, and Ochsner Medical Center.
  • November 5, 2015Lifespan Oncology Clinical Research in Providence, RI, has become the second institution to become active in the Stablemates Trial following IRB approval. The study will open in two locations: The Rhode Island Hospital and The Miriam Hospital. The local principal investigator is Thomas Ng, M.D., Thoracic Surgeon at Rhode Island Hospital and Associate Professor of Surgery at The Warren Alpert Medical School of Brown University.
  • September 17, 2015Henry Ford Health System in Detroit, led by Zane Hammoud, M.D., Thoracic Surgeon, recently became the first IRB-approved subsite for the Stablemates Trial. Congratulations!
  • September 14, 2015The first two patients in the Stablemates Trial have been enrolled at UT Southwestern Medical Center in Dallas. The first patient, a 57-year-old Spanish-speaking female, was randomized to the surgical arm and accepted the assignment. She subsequently underwent sublobar resection at Parkland Memorial Hospital. Scott Reznik, M.D., Associate Professor of Cardiothoracic Surgery at UTSW, performed the surgery. The second patient was an 86-year-old African-American female who was randomized to receive SAbR. She received treatment under the care of Puneeth Iyengar, M.D., Ph.D., Assistant Professor of Radiation Oncology and the study's local PI.